• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    LEGENDARY GLOBAL FOOTBALL STAR RONALDINHO JOINS EXPANSION TEAM OWNERSHIP GROUP IN MAJOR ARENA SOCCER LEAGUE

    5/6/22 9:42:00 AM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BHSE alert in real time by email

    NEW YORK, May 6, 2022 /PRNewswire/ -- Major Arena Soccer League today announced that Brazilian global football legend Ronaldo de Assis Moreira, affectionately known as Ronaldinho Gaúcho or simply Ronaldinho, is joining the world's best indoor league as a Co-Owner of an expansion team.

    (PRNewsfoto/Major Arena Soccer League)

    The soccer icon brings worldwide attention to the Major Arena Soccer League, as his ownership reflects his love of the indoor game and pays tribute to his roots in futsal.

    Considered one of the best players of his generation and regarded by many as one of the greatest players of all time, Ronaldinho won two FIFA World Player of the Year awards and is considered a global icon of the sport. In 2004, he was named by Pelé to the FIFA 100 list of the world's greatest living players. In 2006, Ronaldinho was appointed as a Goodwill Ambassador of the United Nations Office of Sport for Development and Peace.

    Major Arena Soccer League is considered by many to be one of the most exciting styles of soccer and play. MASL games are high scoring, with fast paced play and incredible skill. The arena league features 14 teams that span the United States and Mexico, and play 5 a side. With the recent launch of MASL Properties, and the addition of new commercial partnerships, the league is poised to bring the captivating game to a global audience.

    "I am happy to join the best indoor soccer league in the world. As everyone knows, I am passionate about the game and about life, and I look forward to having fun with this venture. As an MASL team owner, my goals are to use my position to further increase the League's popularity in the USA and around the world, to help improve the already high level of playing and to bring joy and happiness to all fans, especially the children," said Ronaldinho.

    Shep Messing, Chairman of Major Arena Soccer League said, "Pelé, my friend and former teammate from the New York Cosmos, brought Ronaldinho to my attention when he was a teenage prodigy playing in Brazil. I have followed his spectacular career since that day. We are honored to have Ronaldinho join our league and we have great expectations for his continued contributions to the sport, both here and abroad."

    The global icon partners with Co-Owner Robert Striar in the new franchise. Striar, who has been a leading figure in sports and media with his firm M Style, has worked with countless leagues, teams and entertainment companies, as well as investments across the sports & media landscape.

    "We are excited to partner in this new team with such a beloved legend. Ronaldinho's passion for the Arena game and his involvement confirms the upward trajectory of Major Arena Soccer League and its growth. I'm thrilled to have such a wonderful co-owner of our team and partner in our group," said Robert Striar.

    The team location, team name and additional details will be released shortly, however, inquires can be sent to: [email protected]

    ABOUT THE MAJOR ARENA SOCCER LEAGUE

    The Major Arena Soccer League represents the highest level of professional indoor soccer in the world. The MASL features teams across North America, with teams playing coast-to-coast in the United States and Mexico. @MASL_arena, maslsoccer.com [email protected]

    Ronaldinho 

    Ronaldo de Assis Moreira

    Email: [email protected]

    twitter: @10Ronaldinho

    Instagram: @ronaldinho 

    Robert Striar

    Mr. Striar is the founder of M Style Marketing and is an expert in managing strategic platforms for a wide variety of Fortune 500 brands.  Striar also serves as the CEO of Bull Horn Holdings [email protected] twitter: @RobStriar

    M Style Marketing

    M Style Marketing is a global strategy, marketing and branding agency working with leading companies specializing in sports, entertainment, and media. 

    Twitter @MStyleMarketing, Instagram @MStyleMarketing, mstylemarketing.com, [email protected] 

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/legendary-global-football-star-ronaldinho-joins-expansion-team-ownership-group-in-major-arena-soccer-league-301541728.html

    SOURCE Major Arena Soccer League

    Get the next $BHSE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BHSE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BHSE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Cogley Brian bought $3,350 worth of shares (5,000 units at $0.67), increasing direct ownership by 20% to 30,000 units (SEC Form 4)

    4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

    1/17/24 4:03:11 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    New insider Cogley Brian claimed ownership of 30,000 shares (SEC Form 3)

    3 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

    1/17/24 4:01:21 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Desilva Tara bought $1,305 worth of shares (2,266 units at $0.58), increasing direct ownership by 8% to 32,266 units (SEC Form 4)

    4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

    1/16/24 8:14:38 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BHSE
    SEC Filings

    View All

    SEC Form 424B3 filed by Bull Horn Holdings Corp.

    424B3 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

    2/5/24 5:17:01 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B3 filed by Bull Horn Holdings Corp.

    424B3 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

    2/5/24 5:15:23 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bull Horn Holdings Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events

    8-K - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

    2/1/24 5:28:10 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BHSE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Cogley Brian bought $3,350 worth of shares (5,000 units at $0.67), increasing direct ownership by 20% to 30,000 units (SEC Form 4)

    4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

    1/17/24 4:03:11 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Desilva Tara bought $1,305 worth of shares (2,266 units at $0.58), increasing direct ownership by 8% to 32,266 units (SEC Form 4)

    4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

    1/16/24 8:14:38 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Yerace Daniel Alexander bought $7,486 worth of shares (10,850 units at $0.69), increasing direct ownership by 1% to 1,071,455 units (SEC Form 4)

    4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

    1/9/24 5:32:29 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BHSE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Coeptis Therapeutics, Inc. Announces Closing of Business Combination with Bull Horn Holdings Corp.

    Combined company to operate as Coeptis Therapeutics Holdings, Inc. and commence trading on The Nasdaq Global Market under Ticker Symbol "COEP" WEXFORD, Pa. and MIAMI, Oct. 31, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. ("Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced the completion of its business combination with Bull Horn Holdings Corp. (NASDAQ:BHSE), a special purpose acquisition company ("Bull Horn").  In connection with the Business Combination, the combined company has been renamed "Coeptis Therapeutics Holdings, Inc." (the "Company") and its public shares and warrants are expected to commence trading on the Nasdaq G

    10/31/22 7:00:00 AM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Coeptis Therapeutics Enters Exclusive License Agreement with University of Pittsburgh for Rights to SNAP-CAR, a "Multi-Antigen" CAR T Technology

    SNAP-CAR therapy provides a highly programmable therapeutic platform designed to potentially target many tumor types, including hematological malignancies and solid tumors WEXFORD, Pa., Sept. 21, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. (OTC:COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced entry into an exclusive license agreement with the University of Pittsburgh for the rights to a chimeric antigen receptor T cell (CAR T) technology – SNAP-CAR – designed to target multiple antigens simultaneously and potentially address a range of hematologic and solid tumors, including breast and ovarian cancer.

    9/21/22 7:00:00 AM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Coeptis Therapeutics Enters into Exclusive Option Agreement with University of Pittsburgh for Rights to CAR-T Technologies Designed to Target Multiple Cancer Indications, Including Hematologic and Solid Tumors

    Option agreement comprises three technologies and associated patent portfolios Announcement marks the third strategic agreement for Coeptis this quarter designed to bolster its portfolio and complement its innovative cell therapy platforms WEXFORD, Pa., May 17, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. (OTC:COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced entry into an exclusive option agreement with the University of Pittsburgh for the rights to three chimeric antigen receptor T cell (CAR-T) technologies that offer the potential to address a range of hematologic and solid tumors. Among the initial

    5/17/22 7:00:00 AM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BHSE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Bull Horn Holdings Corp.

    SC 13G - Coeptis Therapeutics Holdings, Inc. (0001759186) (Subject)

    2/14/24 3:32:56 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Bull Horn Holdings Corp. (Amendment)

    SC 13G/A - Coeptis Therapeutics Holdings, Inc. (0001759186) (Subject)

    2/6/23 4:25:12 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D filed by Bull Horn Holdings Corp.

    SC 13D - Coeptis Therapeutics Holdings, Inc. (0001759186) (Subject)

    11/7/22 4:10:32 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care